Arvinas logo

Arvinas

ARVN | NASDAQ
Chart Builder DCF Calculator
$6.77
-$0.05 (-0.73%)
At close: Nov 16, 2026, 4:00 PM ET
$6.77
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:43 PM ET
-0.73%

Rating

Updated: Nov 16, 2026
45
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #387/1021 (Top 38%)

Key Statistics

Market Data

Market Cap $443.33M
1D Range
6.70 6.89
52W Range
6.41 13.83

Valuation (TTM)

PE -37.61
PB 0.86
EV/EBITDA 4.96

Valuation (NTM)

Forward PE 42.62
Forward PEG 0.37
Price Target $12.00
Loading financial charts...

Profile

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. ...

Sector Healthcare
Industry Biotechnology
Employees 246
IPO Date Sep 27, 2018
Fiscal Year January - December

Latest News

No news articles available yet.

Earnings

Latest Earnings
Nov 3, 2026
EPS
-$0.82
Beat +10.65%
REV
$500K
Miss -95.96%
Next Earnings
Feb 23, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$12.00
Upside
+77.25%
Buy (7)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.